REBECCA KOOPMAN: Open Payments
NPI 1043883259 · SCOTTSBURG, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$653 in 38 payments from 12 companies in 2025. Trend: 2023 $142 · 2024 $335 · 2025 $653
Food & beverage: $653
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $279 |
| AstraZeneca Pharmaceuticals LP | 4 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $62 |
| Novo Nordisk Inc | 3 | $48 |
| Exact Sciences Corporation | 2 | $36 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Lilly USA, LLC | 1 | $17 |
Products named: VRAYLAR, CAPLYTA, Wegovy, Cologuard Collection Kit, TRELEGY ELLIPTA, REXULTI, AIRSUPRA, TRINTELLIX.
Industry payments across IN — which companies pay providers there.
